NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, News & Analysis

$53.73
-1.30 (-2.36 %)
(As of 08/25/2019 05:05 AM ET)
Today's Range
$53.46
Now: $53.73
$55.94
50-Day Range
$52.81
MA: $59.58
$63.03
52-Week Range
$31.97
Now: $53.73
$64.48
Volume380,830 shs
Average Volume591,371 shs
Market Capitalization$2.68 billion
P/E Ratio5.89
Dividend YieldN/A
Beta1.42
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.97 million
Book Value$24.10 per share

Profitability

Net Income$-29,400,000.00

Miscellaneous

Employees194
Market Cap$2.68 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals shares reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.02) by $0.22. The biopharmaceutical company had revenue of $1.02 million for the quarter, compared to the consensus estimate of $2.91 million. Arena Pharmaceuticals had a net margin of 72.84% and a return on equity of 53.92%. The business's revenue for the quarter was down 74.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.65) EPS. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

5 brokers have issued 12-month price targets for Arena Pharmaceuticals' shares. Their predictions range from $55.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' stock price to reach $66.60 in the next year. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

What is the consensus analysts' recommendation for Arena Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Arena Pharmaceuticals reported impressive first-quarter results wherein earnings and sales surpassed the respective estimates. The company is focused on developing its two pipeline candidates – etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations to focus on the pipeline is prudent, in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry so far this year." (5/15/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News coverage about ARNA stock has been trending positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Arena Pharmaceuticals.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Cytokinetics (CYTK), Advanced Micro Devices (AMD), Micron Technology (MU), Inovio Pharmaceuticals (INO), Canopy Growth (CGC), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), XOMA (XOMA), Zynerba Pharmaceuticals (ZYNE) and Exelixis (EXEL).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.68%), BlackRock Inc. (9.62%), Vanguard Group Inc. (9.18%), Primecap Management Co. CA (3.06%), Perceptive Advisors LLC (2.77%) and Eagle Asset Management Inc. (1.89%). Company insiders that own Arena Pharmaceuticals stock include Jayson Donald Alexander Dallas, Preston Klassen, Steven W Spector and Tina Susan Nova. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Morgan Stanley, Rhenman & Partners Asset Management AB, Cormorant Asset Management LP, Pictet Asset Management Ltd., Pictet Asset Management Ltd., SG Americas Securities LLC and Perceptive Advisors LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, Preston Klassen, Steven W Spector and Tina Susan Nova. View Insider Buying and Selling for Arena Pharmaceuticals.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, ETF Managers Group LLC, Invesco Ltd., Orbimed Advisors LLC, Point72 Asset Management L.P., Wells Fargo & Company MN, Primecap Management Co. CA and Russell Investments Group Ltd.. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $53.73.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.68 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  384 (Vote Underperform)
Total Votes:  730
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel